Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411528 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
A Phase 2 study of Metastatic Hormone Refractory Prostate Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT00411528 is a Phase 2 study of Metastatic Hormone Refractory Prostate Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 185 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT00411528, a Phase 2 study of Metastatic Hormone Refractory Prostate Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG Patupilone
Study Locations (20)
Other
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Colmar
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Rouen
- Novartis Investigative Site - Strasbourg
Florida
- MD Anderson Cancer Center - Orlando CEPO906A2229 - Orlando
- H. Lee Moffitt Cancer Center/University of South Florida Department of Genitourology - Tampa
- Palm Beach Cancer Institute - West Palm Beach
California
- University of California San Diego Dept of Moores Cancer Center - La Jolla
Colorado
- University of Colorado Dept. of Univ. of Colorado - Aurora
Connecticut
- Norwalk Hospital - Norwalk
District of Columbia
- Georgetown University/Lombardi Cancer Center Dept.of Lombardi Cancer Center - Washington D.C.
Georgia
- NorthWest Georgia Oncology Centers Marietta Center - Marietta
Illinois
- University Chicago Hospital StudyCoordinator:CEPO906A2229 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00411528
The ClinicalTrials.gov registry entry for NCT00411528 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Hormone Refractory Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which prednisone is the first listed.
NCT00411528 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00411528 about?
NCT00411528 is a clinical study titled "Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer". The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and th...
What is the current status of trial NCT00411528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2006-09. Estimated completion is 2012-09.
What conditions does trial NCT00411528 study?
This clinical trial studies the following conditions: Metastatic Hormone Refractory Prostate Cancer.
What interventions are being tested in trial NCT00411528?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), Patupilone (DRUG).
Who is sponsoring clinical trial NCT00411528?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00411528 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.